Description
RINVOQ (upadacitinib) extended-release tablets
FDA approves first oral treatment for moderately to severely active Crohn’s disease
FDA has approved Rinvoq (upadacitinib) for adults with moderately to severely active Crohn’s disease who have had an inadequate response or intolerance to one or more tumor necrosis factor blockers. Rinvoq is the first approved oral product available to treat moderately to severely active Crohn’s disease. Crohn’s disease is a chronic inflammatory bowel disease that causes inflammation in the digestive tract. It can affect any part of your digestive tract, and usually affects the small intestine and the beginning of the large intestine.
Upadacitinib is indicated for the treatment of rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, Crohn’s disease, ankylosing spondylitis, and axial spondyloarthritis
Get Access to RINVOQ (upadacitinib) extended-release tablets In India
Medvitaz Pharma is equipped to facilitate the distribution of RINVOQ (upadacitinib) extended-release tablets (prescription medications) worldwide and throughout India upon completion of necessary legal procedures, if applicable.
To inquire about the price of either the branded medication “RINVOQ (upadacitinib) extended-release tablets” or the generic version “upadacitinib tablets” for personal use under patient-specific treatment in various cities including Delhi, Mumbai, Kolkata, Chennai, Bangalore, Hyderabad, Ahmedabad, Pune, Surat, Jaipur, Coimbatore, Noida, Gurgaon, Punjab, Chandigarh, Bhubaneswar, Arunachal Pradesh, Assam, Manipur, Meghalaya, Mizoram, Nagaland, Tripura, Sikkim, and others in India, please fill out the request form. Upon receiving your request and assessing the delivery process, we will provide you with an estimated price for the medication within 24 hours.
For any inquiries or assistance, please reach out to our Patient Support Team. We are available to assist you from Monday to Friday, between 9:00 and 19:00 IST. You can contact us via email at [email protected], toll-free at +91 8750295029, or through WhatsApp at +91-8750295029.